Brief: Sinomab Bioscience Says Entered Collaboration Agreement With D2M
22/07/2020 15:08
July 22 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* ENTERED COLLABORATION AGREEMENT WITH D2M REGARDING NOVEL
DRUG
TARGETS IDENTIFICATION
* UNIT TO PURCHASE FROM D2M 38.17% OF IMMEDIATE POST-CLOSING
SHARE
PERCENTAGE IN D2M FOR US$5 MILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKS59G6ks
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience